Foundation model-enhanced multimodal radiomics for predicting response to chemo-immunotherapy in advanced lung squamous cell carcinoma - Top-Institutions - MDSpire

Enhanced Multimodal Radiomics Utilizing Foundation Models for Anticipating Chemo-Immunotherapy Outcomes in Advanced Lung Squamous Cell Carcinoma

  • By

  • Zhichao Wang

  • Yang Zhang

  • Chuchu He

  • Meng Wang

  • Jun Cai

  • July 20, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    our hospital
    our hospital

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #2

    GARNET trial
    GARNET trial

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #3

    North Estonia Medical Centre (NEMC) Foundation
    North Estonia Medical Centre (NEMC) Foundation

    Tallinn, Estonia

    Key Differentiators

    • Oncology

  • #4

    Stanford NSCLC Radiogenomics
    Stanford NSCLC Radiogenomics

    Stanford, California

    Key Differentiators

    • Oncology

  • #5

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Foundation model-enhanced multimodal radiomics for predicting response to chemo-immunotherapy in advanced lung squamous cell carcinoma

  • by Zhichao Wang, Yang Zhang, Chuchu He, Meng Wang, Jun Cai

  • July 20, 2026

Related Content

A prehabilitation-enhanced nomogram for predicting early pulmonary recovery failure after lung tumor surgery: development and multicenter validation

Social genomics and cancer – untangling nature from nurture in squamous cell carcinoma outcomes

Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations